Epitope-Based Immune Detection Kits for Rapid Viral Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting immune responses to viral pathogens, such as SARS-CoV-2, are often slow, unreliable, and require significant resources, hindering the development of effective public health measures and individual release from physical distancing constraints.
Innovation Solution
Development of point-of-need compositions and kits containing antigens with specific T-cell recognized epitopes, anticoagulation agents, and optional adjuvants, which are stable for extended periods, allowing for rapid detection of immune responses in subjects through incubation of blood samples and subsequent analysis of immune-response analytes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If current methods for detecting immune responses are used, then detection can be performed, but the detection process is slow and requires significant resources
Solution Approach 1:
The patent extracts and isolates specific T-cell recognized epitopes from entire viral antigens. By using only the critical epitopic regions (e.g., specific peptide sequences like those from SARS-CoV-2 spike protein, nucleocapsid protein, or other viral proteins) rather than complete viral antigens, the detection system achieves faster and more efficient immune response detection while reducing resource requirements.
Solution Approach 2:
The patent segments the complex immune detection process into distinct components: (1) isolated epitopic peptides as stimulants, (2) specific immune cell populations (T cells, B cells, NK cells) as targets, and (3) measurable immune response parameters (cytokine production, cell proliferation, activation markers). This segmentation enables parallel processing and faster overall detection.
2Reliability
If current immune response detection methods are used, then detection can be performed, but reliability is insufficient
Solution Approach 1:
The patent applies local quality by focusing detection on specific high-value regions (epitopes) within viral antigens that are most immunogenic and T-cell recognizable. Rather than using entire antigens, the invention concentrates on localized peptide sequences (e.g., 9-20 amino acid epitopes from specific viral proteins) that provide superior detection reliability and precision for determining immune response status.
3Reliability
If comprehensive immune detection is performed, then accurate results are obtained, but resource consumption increases significantly
Solution Approach 1:
The invention extracts only the essential epitopic components from complete viral antigens, using minimal peptide sequences (9-20 amino acids) that are sufficient to trigger specific T-cell responses. This extraction approach maintains detection accuracy while dramatically reducing the quantity of antigenic material and resources required compared to using entire viral proteins or whole-cell antigens.
4Duration of action of stationary object
If stable antigen compositions are used, then extended storage is possible, but formulation complexity increases
Solution Approach 1:
The patent applies parameter changes by modifying the physical and chemical state of epitopic peptides through various formulation approaches: lyophilized (freeze-dried) powder forms, aqueous suspensions, or solid-state formulations. These parameter changes enable extended storage stability at different temperature conditions while maintaining epitope immunogenicity and T-cell recognition capability, effectively resolving the stability-formulation complexity trade-off.
Data Source
AI summary
Described herein are compositions and methods for detecting immune response to pathogens. Also described herein are methods and systems utilizing the compositions for detecting adaptive immunity.